Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | PTPRE | P23469 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566015 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2APTPRCPTPN2 | |
| SCHEMBL16247169 | 0.85 | KDM4E (0.47) | KDM4ECDK8PLK4DCLK1ROCK2 | |
| SCHEMBL4792436 | 0.83 | CDK8 (0.47) | ALDH1A1KDM4EHPGDSMN1; SMN2CDK8 | |
| SCHEMBL5925880 | 0.81 | PTPRC (0.45) | ALDH1A1PTPRCPTPN2PTPN1PTPRB | |
| SCHEMBL27982631 | 0.80 | PTPRC (0.42) | ALDH1A1MEN1KMT2APTPRCPTPN2 | |
| SCHEMBL4151886 | 0.79 | PTPRC (0.44) | ALDH1A1KMT2APTPRCPTPN2PTPN1 | |
| SCHEMBL1779836 | 0.79 | POLB (0.49) | ALDH1A1PTPRCPTPN2PTPN1PTPRB | |
| SCHEMBL31403547 | 0.79 | POLB (0.49) | ALDH1A1PTPRCPTPN2PTPN1PTPRB | |
| SCHEMBL23680893 | 0.76 | SPR (0.42) | HPGDSMN1; SMN2PLK4MAP4K4ROS1 | |
| SCHEMBL6493825 | 0.75 | NUDT1 (0.41) | ALDH1A1MEN1KMT2APTPRCPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | MYOFORTE THERAPEUTICS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1560582-A4 | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006112828-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1560582-A2 | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004032874-A2 | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | ALDH1A1 145/4885MEN1 3691/4885KMT2A 4208/4885 |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | ALDH1A1 145/4885MEN1 3691/4885KMT2A 4208/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | ALDH1A1 183/4885MEN1 3731/4885KMT2A 4304/4885 |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | HPGD, HPGDS, GCDH | ALDH1A1 37/4885MEN1 4715/4885KMT2A 3278/4885 |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | ALDH1A1 1498/4885MEN1 3682/4885KMT2A 1561/4885 |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK4 | ALDH1A1 1971/4885MEN1 3655/4885KMT2A 1367/4885 |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | ALDH1A1 145/4885MEN1 3691/4885KMT2A 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.